"bye, need for IV access " and "hy," inside of two speech bubbles icons.

subcutaneous
administration

One monthly* dose.¹Flexible administration.¹

HyQvia delivers long-lasting,^† monthly* protection for your patients with PI who want a little more time between infusions.

*Every 3 or 4 weeks.

Median infusion time was 2.08 (0.83-4.68) hours vs 2.33 (0.92-6.33) for IVIG in the clinical trial.

^†Between infusions.

With HyQvia, monthly* SCIG dosing could mean fewer infusions for your patients¹

Number of infusions per year

Grey and yellow bar graph with number of infusions for HYQVIA and cSCIG.

50^%

Patients’ number of infusions per year could be reduced by 50% or more

*Every 3 or 4 weeks.

cSCIG=conventional subcutaneous immune globulin.

Hyaluronidase is dosed at a fixed ratio of 0.5 mL rHuPH20 solution per 10 mL Immune Globulin Infusion 10% (Human) solution. This is supplied as part of a dual unit vial. Administer the full content of the Hy vial/s for both a full and partial dose of IG.

HyQvia dosing information

HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] comes in a dual vial unit—one vial of Immune Globulin Infusion 10% (Human) Solution [IG 10%] and one vial of Recombinant Human Hyaluronidase.¹

The HyQvia dose is based on the immune globulin (IG 10%) component, which provides the therapeutic effect. Dispersion and absorption of the 10% IG is facilitated by the Recombinant Human Hyaluronidase.¹

HyQvia initial monthly* dosing (following ramp-up) may vary depending on whether patients are switching from intravenous immune globulin (IVIG) treatment or conventional subcutaneous immune globulin (SCIG) treatment.¹

*Every 3 or 4 weeks.

Dosing Calculator

HyQvia dosing calculator

Determine dosage range

To determine the dosage ranges for a patient, select the weight closest to the patient’s weight in the window on the left. Dosage ranges will appear in grams. See Full Prescribing Information for additional dosage recommendations. A conversion factor of 2.2046 lb/kg is used to convert the patient’s weight to kilograms. The values displayed are rounded to the nearest decimal point.

What is the patient's weight?

lb or kg

Dosage range to be prescribed every 3-4 weeks or per patient needs

300 mg/kg =

400 mg/kg =

500 mg/kg =

600 mg/kg =

This calculator does not represent every possible weight calculation. Weights begin as 24 lb and increase in 4 lb increments to 288 lb.

Select available HyQvia vial combinations based on dosage

When available HyQvia solution vial sizes cannot be combined to equal the calculated IG dose, the dose must be rounded up or down.
The Physicians should make this determination based on their clinical judgment and HyQvia vial sizes.

HyQvia doses, based on available vial combinations, are shown in the table below.

HyQvia doses (g) (based on available vial combinations)*
2.5	5	7.5	10
12.5	15	17.5	20
22.5	25	27.5	30
32.5	35	37.5	40
42.5	45	47.5	50
52.5	55	57.5	60
62.5	65	67.5	70
72.5	75	77.5	80

*HyQvia is available in 2.5, 5, 10, 20, and 30 g vials of IG 10%. This table shows possible vial combinations at increasing 2.5 g increments, reading from left to right and top to bottom.

Switching patients to HyQvia

When switching to HyQvia, dose and frequency are determined by whether a patient is switching from an IVIG or a SCIG.¹

Patients switching from IVIG treatment

Same dose and frequency of IVG
(after initial ramp-up)

Patients switching from SCIG

300 to 600 mg/kg at 3- or 4-week intervals
(after initial ramp-up)

Ramping Up

How to ramp up HyQvia

There is a ramp-up period for HyQvia which allows patients to become familiar with the volumes required for a full 3- or 4-week treatment.¹

Initial treatment and HyQvia ramp-up schedule

Treatment with HyQvia is initiated by gradually increasing the dose and decreasing the frequency from a 1-week dose to a 3- or 4-week dose.

Dosage during this ramp-up period is calculated by dividing the total 3- or 4-week therapeutic dose as shown in the graph.

The first dose of HyQvia should be given approximately 1 week after the last infusion of the previous treatment.

To access patient resources, visit Access & Support.

For more comprehensive information on HyQvia dosing, see Full Prescribing Information

Yellow ramping-up bar graph for 30-gram dose of HYQVIA.

Infusion Experience

Infusion experience

Over the course of the efficacy and extension trials of HyQvia in ~3.5 years (2959 infusions), there were no clinically observable changes in the skin or subcutaneous tissue.¹

Individual results may vary.

Pre-Infusion

Patient weight: 168 lb
Volume: 500 mL
Number of Infusion sites: 1

Post-Infusion

Results in a diffuse, temporary, localized swelling

24 Hours Post-Infusion

Infusion site swelling generally resolved within 1 to 3 days

Pre-Infusion

Patient weight: 162 lb
Volume: 300 mL
Number of Infusion sites: 2

Post-Infusion

Side effects include acute tenderness

24 Hours Post-Infusion

Infusion site swelling generally resolved within 1 to 3 days

Fill out and submit this form to initiate your patient’s HyQvia

Download form

Infusion time estimator

See how HyQvia patients could spend less than half the time infusing compared to conventional IVIG¹

How long do they spend infusing?

Monthly dose (in grams)

IVIG
monthly

HyQvia
1 site

HyQvia
2 sites

Monthly

Yearly

*Every 3 or 4 weeks.

Review safety information

Review Important Safety Information, including Contraindications and other specific Warnings and Precautions to consider when prescribing and monitoring patients treated with HyQvia.

See safety information

Flexible administration options¹

You can work with your patients to determine:

Either 1 or 2 infusion sites
- A second site can be used at the discretion of the physician and patient based on tolerability and total volume
Infusion site location in either the abdomen or the thighs
Every 3- or 4-week treatment intervals
Infuse at home, after adequate training, or in-center

Infusion options for your patients

To better meet the needs of your patients, there are 2 different methods available to prepare and infuse HyQvia.¹ Depending on the specialty pharmacy, patients will receive one of the following pump options:

Peristaltic pump and pooling bag

Hy component is infused by manual syringe push. IG component is infused by the peristaltic pump.

Download our brochure on how to infuse HyQvia with a peristaltic pump.

Watch our peristaltic pump infusion video:

0:00 Get familiar with hy5
3:35 hy1: Get ready
4:31 hy2: Prepare the hyaluronidase, or Hy
6:42 hy3: Prepare the immune globulin, or IG
10:37 hy4: Infuse
15:30 hy5: Finsh up

Syringe driver pump

Hy component is infused by manual syringe push or the syringe driver pump. IG component is infused by the syringe driver pump.

A range of syringe driver pumps meet the criteria to administer HyQvia.

Download our brochure on how to infuse HyQvia with a syringe driver pump.

Financial and patient support

Financial and educational resources for your patients

See resources

HyQvia resources

Help your patients get the support they need to take HyQvia as you prescribed

Learn how

HyQvia ancillaries guide

Overview of all the elements needed to infuse HyQvia

Download guide

Pediatrics

Starting Patients

Reference

HyQvia. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2024.

Contact a Rep

IMPORTANT SAFETY INFORMATION including BOXED WARNING for Thrombosis

INDICATION

HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients two years of age and older. HYQVIA is for subcutaneous use only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin (IG) products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human IG
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG
Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA
Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)

Warnings and Precautions

Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis.

Thrombosis: Has been reported to occur following treatment with IG products, including HyQvia and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Immunogenicity of Recombinant Human Hyaluronidase (rHuPH20): Non-neutralizing antibodies to the Recombinant Human Hyaluronidase component can develop. The clinical significance of these antibodies or whether they interfere with fertilization in humans is unknown.

Aseptic Meningitis Syndrome: Has been reported with use of IG, including HyQvia and may occur more frequently in females. The syndrome usually begins within several hours to two days following IG treatment.
Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae.

Hemolysis: HYQVIA contains blood group antibodies which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing.

Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with intravenous (IV) use of IG products, especially those containing sucrose. Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and consider lower, more frequent dosing. If renal function deteriorates, consider discontinuation.

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Transfusion-Related Acute Lung Injury: Non-cardiogenic pulmonary edema may occur with IV administered IG. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.

Transmittable Infectious Agents: Because HYQVIA is made from human plasma, it may carry a risk of transmitting infectious agents (e.g. viruses, other pathogens). No cases of transmission of viral diseases or variant Creutzfeldt-Jakob disease (vCJD) have been associated with HYQVIA.

Interference with Lab Tests: False positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.

Adverse Reactions

The most common adverse reactions observed in >5% of patients in the clinical trials were: local adverse reactions including pain, erythema, edema, and pruritis, and systemic adverse reactions including, headache, antibody formation against Recombinant Human Hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use in Specific Populations

Pregnancy: Limited human data are available on the use of HyQvia during pregnancy. The effects of antibodies to the Recombinant Human Hyaluronidase on the human embryo or fetal development are unknown. It is not known whether HyQvia can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. HyQvia should be given to a pregnant woman only if clearly needed.

Please click for Full Prescribing Information.

INDICATION

HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients two years of age and older. HYQVIA is for subcutaneous use only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin (IG) products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human IG
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG
Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA
Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)

Warnings and Precautions

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Adverse Reactions

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use in Specific Populations

Please click for Full Prescribing Information.

©2024 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA^®, the TAKEDA Logo^®, and the TAKEDA Patient Support Logo^® are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. HYQVIA^® and MYIGSOURCE™ are trademarks or registered trademarks of Baxalta Incorporated.
US-HYQ-1214v1.0 05/24

One monthly* dose.1 Flexible administration.1

With HyQvia, monthly* SCIG dosing could mean fewer infusions for your patients1

HyQvia dosing information

HyQvia dosing calculator

Switching patients to HyQvia

How to ramp up HyQvia

Infusion experience

Infusion time estimator

Review safety information

Flexible administration options1

Infusion options for your patients

Peristaltic pump and pooling bag

Syringe driver pump

Financial and patient support

HyQvia resources

HyQvia ancillaries guide

Thank you for visiting

Thank you for visiting

Healthcare professionals

One monthly* dose.¹Flexible administration.¹

With HyQvia, monthly* SCIG dosing could mean fewer infusions for your patients¹

Flexible administration options¹